- The US FDA has granted expanded approval to the Enstilar foam, 0.005%/0.064% supported by the Enstilar Pediatric study evaluating it in adolescents with plaque psoriasis aged ≥12yrs. The FDA has extended its market exclusivity by an additional six mos. to Dec 10, 2031
- Additionally, the FDA has approved Taclonex topical suspension for scalp and body plaque psoriasis in patients aged ≥12yrs.
- Enstilar Foam is a combination of calcipotriene, a vitamin D analog, and betamethasone dipropionate, a corticosteroid while Taclonex is a combination of betamethasone and calcipotriene in which betamethasone prevents the release of the substance causing inflammation in the body
Click here to read full press release/ article | Ref: BusinessWire | Image: Pharmastar